Corgenix and Autoimmune Technologies Complete Development of
Diagnostic Product for Fibromyalgia
Test Kit for Anti-Polymer Antibodies (APA) to Be Launched This Year Through
Corgenix Distribution Organization
WESTMINSTER, Colo., Aug. 19 /PRNewswire-FirstCall/ -- Corgenix Medical
Corporation (OTC:CONX) (BULLETIN BOARD: CONX) announced today that it has
completed the development of the APA ELISA test kit for diagnosing
fibromyalgia. The product was developed under a Development and Manufacturing
Agreement with Autoimmune Technologies, LLC (Autoimmune), a New Orleans
biomedical company. The new product employs Autoimmune's patented technology,
and is expected to enter FDA clinical trials in the United States this
September.
The Development and Manufacturing Agreement provides Corgenix with the
exclusive rights to manufacture the kit, which detects anti-polymer antibodies
(APA) and serves as the first serum-based assay specific for fibromyalgia, a
common pain and fatigue disorder. Corgenix and Autoimmune are collaborating on
distribution of the product, and expect to launch the patented APA ELISA test
kit this September in Europe through Corgenix' international distribution
network. International distribution will be coordinated by Corgenix'
subsidiary in the UK. The product will subsequently be available in the US if
the FDA grants regulatory clearance.
"Current data suggests that APA-positive fibromyalgia patients comprise the
majority of fibromyalgia patients," said Luis Lopez, MD, Chairman and CEO of
Corgenix. "This test is intended for use as an aid in the diagnosis of
patients presenting with the symptoms and signs of fibromyalgia syndrome, as an
aid in differentiating fibromyalgia patients from patients with other
autoimmune diseases, and as an aid in determining which fibromyalgia patients
have an immune response that is associated with their symptoms." Fibromyalgia Syndrome (FMS) is a common chronic disorder that afflicts millions
of individuals, primarily women. It appears to have multiple causes. FMS signs
and symptoms include widespread pain, specific painful "tender points,"
fatigue, stiffness, sleep disturbance, headache, depression, anxiety, cognitive
problems and other symptoms. Not all of the symptoms are present in every
patient, and each patient may have different symptoms at different times. The
American College of Rheumatology (ACR) criteria for fibromyalgia require that a
patient manifest localized pain in at least 11 of 18 possible tender points and
have a history of chronic widespread pain of greater than three months'
duration. Clinical physicians often consider other symptoms as well when
making a diagnosis of FMS. However, all of the diagnostic criteria now
generally used for fibromyalgia are subjective, and this leads many people who
aren't suffering from fibromyalgia to believe that FMS is a psychological
disorder rather than a physical disorder.
"The APA Assay is the first specific clinical laboratory test for objectively
identifying fibromyalgia patients," said Russell B. Wilson, PhD, President and
Chief Science Officer of Autoimmune Technologies. "The APA ELISA test detects
IgG anti-polymer antibodies in human serum. Research has shown that not only
are these antibodies detected in the majority of fibromyalgia patients tested,
but antibody titers also correlate with the severity of symptoms in these
patients." Between 2% and 5% of adult women in the US are believed to have received a
diagnosis of fibromyalgia, but the total number of FMS sufferers might be far
greater. Researchers have found that, although half of US women have none of
the 18 possible fibromyalgia tender points, approximately 20% of US women may
have 6 or more of these tender points. Other research has determined that the
direct medical costs of fibromyalgia, which include patient visits to multiple
physicians to obtain a diagnosis, may exceed more than $15 billion per year in
the US alone.
In discussing the potential market for the APA ELISA test kit in the context of
these figures, Doug Simpson, President of Corgenix, said, "Although other
laboratory markers exist, this is the only serum-based lab test that
specifically picks up fibromyalgia patients. Research findings to date
strongly suggest that fibromyalgia in APA-positive patients is associated with
an abnormal immune system response. As a result, we expect the APA ELISA test
to be useful not only in helping physicians make an initial diagnosis of
fibromyalgia but also in indicating to them which of their fibromyalgia
patients might benefit from one or more of the many existing drugs or therapies
that modulate the immune system." Mr. Simpson went on to say, "This is a very important step forward for both of
our companies. Obtaining rights to this unique technology represents an
excellent strategic fit for Corgenix, and expands our business base in markets
that we currently serve. We see a very attractive market potential worldwide
for this testing, and think this brings significant opportunity to our company. In addition, the relationship provides Autoimmune Technologies with access to
a company with a global network to distribute its unique technology to the
world markets." "We are happy to be working with Corgenix in what we feel is a very important
endeavor," said Michael D. Charbonnet, CEO of Autoimmune. "Not since the
discovery of rheumatoid factors in the 1940s has a laboratory test had the
potential to so dramatically change the perception of a medical disorder.
Rheumatoid factors provided the earliest laboratory evidence that rheumatoid
arthritis was a 'real disease' and led to dramatic advances in treatment for
it. We believe that the APA Assay has the ability to do the same thing for
fibromyalgia, formally establishing fibromyalgia as a separate and distinct
physical disease and leading to greatly improved patient outcomes." About Corgenix Corgenix is a leader in the development and manufacture of anti- Phospholipid
test kits and other unique diagnostic products for cardiovascular disease and
thrombotic risk, being the first on the market with an FDA cleared assay for
anti-Cardiolipin (aCL). The company is based in metropolitan Denver and is
focused on the development of specialized diagnostic kits for immunology
disorders, vascular diseases and bone and joint diseases. Corgenix diagnostic
products are commercialized for use in clinical laboratories throughout the
world. More information about the company can be found on its Web site,
http://www.corgenix.com/.
Corgenix has previously announced a planned merger with Genesis Bioventures,
Inc., (Genesis) (AMEX:GBI), a biomedical corporation focusing on the
development and marketing of novel diagnostics and therapeutics.
About Autoimmune Technologies Autoimmune Technologies is a privately held early-stage biomedical company
based in New Orleans. Autoimmune has licensed several proprietary breakthrough
research discoveries, including the APA Assay, from Tulane University School of
Medicine and is working to make them commercially available to the medical
community. More information about the company can be found on its Web site,
http://www.autoimmune.com/.
Statements in this press release that are not strictly historical facts are
"forward looking" statements (identified by the words "believe," "estimate,"
"project," "expect" or similar expressions) within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, continued acceptance of the
Company's products and services in the marketplace, competitive factors,
changes in the regulatory environment, and other risks detailed in the
Company's periodic report filings with the Securities and Exchange Commission.
The statements in this press release are made as of today, based upon
information currently known to management, and the company does not undertake
any obligation to publicly update or revise any forward-looking statements. DATASOURCE: Corgenix Medical Corporation CONTACT: William Critchfield, CFO of Corgenix Medical Corporation, +1-303-453-8903, ; or Michael D. Charbonnet, CEO of Autoimmune Technologies, +1-504-529-9944, Web site: http://www.autoimmune.com/ http://www.corgenix.com/
|